Cardiovascular Diseases
Conditions
Brief summary
The purpose of this study is to identify gene variants that increase risk of cardiovascular disease (CVD) and type 2 diabetes, particularly genes related to stress factors.
Detailed description
In Aim 3, 100 subjects who participated in previous studies will be recruited to test the ability of a 5HTR2C agonist (lorcaserin) to increase and antagonist (ziprasidone) to reduce cortisol response to mental and metabolic stress in men carrying the rs6318 C allele and women in the rs6318 CC genotype of 5HTR2C. Lorcaserin is serotonin receptor agonist indicated for use as a weight loss drug. Ziprasidone is an antipsychotic indicated for treatment of bipolar disorder. Subjects will be treated with a single dose of each drug, 1 to 2 weeks apart, followed by a mental stress test and an oral glucose tolerance test with multiple blood draws. Each subject will also receive a placebo drug during one of the study visits.
Interventions
DRUGZiprasidone
Given by mouth, single dose of 60 mg.
DRUGLorcaserin
Given by mouth, single dose of 20 mg.
DRUGPlacebo Oral Tablet
Given by mouth, single dose.
Sponsors
National Heart, Lung, and Blood Institute (NHLBI)
Duke University
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men and women who have been enrolled in the STRRIDE, ENHANCED, and/or REMIT studies age 18 years or greater. * Ability and willingness to provide informed consent. * Individuals with specific genotypes as determined from our previous work on their samples through Aim 1 of this project.
Exclusion criteria
* Women who are known to be pregnant, intend to become pregnant, or breast-feeding will be excluded. Women who are of child bearing potential (under age 55) will be informed that they will need to have their urine tested for pregnancy and that they should not participate in the research if they are not willing to have the Investigators provide them with information on positive pregnancy test results. Subjects will be informed that the pregnancy testing is not being performed for clinical purposes and that the testing is not a substitute for their regular medical care if they need to know whether or not they may be pregnant. * History of Type II diabetes mellitus. * History of prolonged QT interval. * Participation in an investigational drug trial within the last 30 days. * Already taking either ziprasidone or lorcaserin or any potential confounding medications, for example, other weight loss medications or psychotropic medications. * Unwillingness to fast for at least 6 hours prior to the research study visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in peak blood cortisol during the metabolic stress of an OGTT | Baseline to 3-hours post OGTT |
| Change in peak blood cortisol during the metabolic stress of a mental stress test | Baseline to 3-hours post mental stress test |
Secondary
| Measure | Time frame |
|---|---|
| Area-Under-the-Curve Glucose | Baseline to 2-hours post OGTT |
| Matsuda Insulin Resistance Index | Baseline to 2-hours post OGTT |
Countries
United States
Outcome results
None listed